ASH 2023 | Barriers to enrollment in clinical trials for patients with NHL who have progressed on CAR-T therapy
In this video, Evandro Bezerra, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, highlights the barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have progressed following CAR T-cell therapy. This study found that around half of patients would not be eligible for clinical trial enrollment, and Dr Bezerra recommends that exclusion criteria are adapted to be more inclusive of this patient population, in which many patients have a poor prognosis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
